EXAS Fundamental Analysis - EXACT SCIENCES CORP

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to EXAS. EXAS was compared to 541 industry peers in the Biotechnology industry. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. EXAS is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.

In the past year EXAS had a positive cash flow from operations.

EXAS had negative earnings in each of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.

1.2 Ratios

EXAS has a better Return On Assets (-17.34%) than 79.30% of its industry peers.

EXAS's Return On Equity of -40.71% is fine compared to the rest of the industry. EXAS outperforms 70.98% of its industry peers.

		Industry Rank	Sector Rank
ROA	-17.34%
ROE	-40.71%
ROIC	N/A

ROA(3y)-10.17%

ROA(5y)-11.23%

ROE(3y)-23.27%

ROE(5y)-24.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EXAS has a Gross Margin of 68.19%. This is amongst the best in the industry. EXAS outperforms 80.22% of its industry peers.

EXAS's Gross Margin has declined in the last couple of years.

EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	68.19%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.06%

GM growth 5Y-1.57%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for EXAS has been increased compared to 1 year ago.

EXAS has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, EXAS has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.43, we must say that EXAS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of EXAS (1.43) is better than 64.33% of its industry peers.

The Debt to FCF ratio of EXAS is 18.77, which is on the high side as it means it would take EXAS, 18.77 years of fcf income to pay off all of its debts.

Looking at the Debt to FCF ratio, with a value of 18.77, EXAS belongs to the top of the industry, outperforming 91.31% of the companies in the same industry.

A Debt/Equity ratio of 0.94 indicates that EXAS is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.94, EXAS is doing worse than 75.79% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	18.77
Altman-Z	1.43

ROIC/WACCN/A

WACC8.72%

2.3 Liquidity

A Current Ratio of 2.89 indicates that EXAS has no problem at all paying its short term obligations.

EXAS has a worse Current ratio (2.89) than 64.69% of its industry peers.

A Quick Ratio of 2.56 indicates that EXAS has no problem at all paying its short term obligations.

EXAS has a Quick ratio of 2.56. This is in the lower half of the industry: EXAS underperforms 66.73% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.89
Quick Ratio	2.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -465.63%.

EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.56%.

The Revenue has been growing by 25.78% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-465.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%88.89%

Revenue 1Y (TTM)12.56%

Revenue growth 3Y16.01%

Revenue growth 5Y25.78%

Sales Q2Q%15.99%

3.2 Future

Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.32% on average per year.

EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.08% yearly.

EPS Next Y89.28%

EPS Next 2Y43.73%

EPS Next 3Y30.79%

EPS Next 5Y20.32%

Revenue Next Year14.7%

Revenue Next 2Y13.51%

Revenue Next 3Y12.96%

Revenue Next 5Y10.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 146.90, the valuation of EXAS can be described as expensive.

Based on the Price/Forward Earnings ratio, EXAS is valued cheaper than 86.88% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, EXAS is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	146.9

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaper than 89.28% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, EXAS is valued cheaply inside the industry as 92.05% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	81.95
EV/EBITDA	178.77

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

A more expensive valuation may be justified as EXAS's earnings are expected to grow with 30.79% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y43.73%

EPS Next 3Y30.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EXAS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EXACT SCIENCES CORP

NASDAQ:EXAS (9/12/2025, 8:00:02 PM)

After market: 52.92 -1.02 (-1.89%)

53.94

-2.06 (-3.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-06 2025-08-06/amc

Earnings (Next)11-03 2025-11-03/amc

Inst Owners98.76%

Inst Owner Change-4.01%

Ins Owners0.87%

Ins Owner Change2.49%

Market Cap10.21B

Analysts85

Price Target64.66 (19.87%)

Short Float %5.06%

Short Ratio2.97

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)27.73%

Min EPS beat(2)-39.07%

Max EPS beat(2)94.53%

EPS beat(4)2

Avg EPS beat(4)-333.88%

Min EPS beat(4)-1391.93%

Max EPS beat(4)94.53%

EPS beat(8)5

Avg EPS beat(8)-143.38%

EPS beat(12)9

Avg EPS beat(12)-87.39%

EPS beat(16)11

Avg EPS beat(16)-65.6%

Revenue beat(2)2

Avg Revenue beat(2)1.64%

Min Revenue beat(2)0.62%

Max Revenue beat(2)2.65%

Revenue beat(4)2

Avg Revenue beat(4)-0.05%

Min Revenue beat(4)-3.19%

Max Revenue beat(4)2.65%

Revenue beat(8)2

Avg Revenue beat(8)-0.26%

Revenue beat(12)6

Avg Revenue beat(12)1.07%

Revenue beat(16)10

Avg Revenue beat(16)1.66%

PT rev (1m)-8.13%

PT rev (3m)-8.51%

EPS NQ rev (1m)37.72%

EPS NQ rev (3m)-703.36%

EPS NY rev (1m)22.61%

EPS NY rev (3m)-5.69%

Revenue NQ rev (1m)1.69%

Revenue NQ rev (3m)1.95%

Revenue NY rev (1m)1.64%

Revenue NY rev (3m)1.68%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	146.9
P/S	3.47
P/FCF	81.95
P/OCF	33.42
P/B	4.14
P/tB	N/A
EV/EBITDA	178.77

EPS(TTM)-5.43

EYN/A

EPS(NY)0.37

Fwd EY0.68%

FCF(TTM)0.66

FCFY1.22%

OCF(TTM)1.61

OCFY2.99%

SpS15.53

BVpS13.04

TBVpS-4.56

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.34%
ROE	-40.71%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	68.19%
FCFM	4.24%

ROA(3y)-10.17%

ROA(5y)-11.23%

ROE(3y)-23.27%

ROE(5y)-24.85%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.06%

GM growth 5Y-1.57%

F-Score4

Asset Turnover0.51

Health

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	18.77
Debt/EBITDA	35.11
Cap/Depr	83.3%
Cap/Sales	6.16%
Interest Coverage	N/A
Cash Conversion	459.82%
Profit Quality	N/A
Current Ratio	2.89
Quick Ratio	2.56
Altman-Z	1.43

F-Score4

WACC8.72%

ROIC/WACCN/A

Cap/Depr(3y)84.38%

Cap/Depr(5y)130.41%

Cap/Sales(3y)7.28%

Cap/Sales(5y)12.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-465.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%88.89%

EPS Next Y89.28%

EPS Next 2Y43.73%

EPS Next 3Y30.79%

EPS Next 5Y20.32%

Revenue 1Y (TTM)12.56%

Revenue growth 3Y16.01%

Revenue growth 5Y25.78%

Sales Q2Q%15.99%

Revenue Next Year14.7%

Revenue Next 2Y13.51%

Revenue Next 3Y12.96%

Revenue Next 5Y10.08%

EBIT growth 1Y16.87%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year321.21%

EBIT Next 3Y82.67%

EBIT Next 5Y52.64%

FCF growth 1Y214.96%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y316.93%

OCF growth 3YN/A

OCF growth 5YN/A

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens